RENOVARO INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.51 USD | +2.72% |
|
-10.59% | -52.05% |
| Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M |
|---|---|---|---|---|---|
| Net income 2022 | -113M | Net income 2023 | -39M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M | Net Debt 2023 | 3.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -6.96% | ||
| 1 week | -25.38% | ||
| Current month | -6.96% | ||
| 1 month | -51.00% | ||
| 3 months | -66.05% | ||
| 6 months | -49.31% | ||
| Current year | -53.63% |
1 week
1.24
2.10
1 month
1.242.97
Current year
1.245.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 18-01-22 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-20 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 19-12-31 |
Avram Miller
BRD | Director/Board Member | - | 23-10-10 |
James Sapirstein
BRD | Director/Board Member | 63 | 18-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 18 M€ | +2.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 1.51 | +2.72% | 186 976 |
| 24-05-01 | 1.47 | -6.96% | 451,282 |
| 24-04-30 | 1.58 | +1.28% | 1,006,467 |
| 24-04-29 | 1.56 | +1.96% | 439,601 |
| 24-04-26 | 1.53 | -10.00% | 1,044,301 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -53.63% | 211M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +3.96% | 22.25B | |
| -14.77% | 21.68B | |
| -8.70% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- RENB Stock
